Artiva Biotherapeutics, Inc. cash flow statement

In fiscal 2025, Artiva Biotherapeutics, Inc.'s operations generated −$76.8m of cash; it spent $2.6m on capital projects, leaving free cash flow of −$79.3m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Artiva Biotherapeutics, Inc.: cash flow statement, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	−47	−55	−77
Depreciation and amortisation	2	2	3
Stock-based pay	7	7	7
Capital spending	3	1	3
Free cash flow	−51	−56	−79
Free cash flow after stock pay	−58	−63	−86
Shares issued	—	167	0

US$ millions unless shown otherwise. Fiscal quarters.

Artiva Biotherapeutics, Inc.: cash flow statement, quarterly
Quarter	2023 Q2Jun 2023	2023 Q3Sept 2023	2023 Q4Dec 2023	2024 Q1Mar 2024	2024 Q2Jun 2024	2024 Q3Sept 2024	2024 Q4Dec 2024
Cash from operations	—	−11	−11	−15	−14	−12	−15
Depreciation and amortisation	1	1	1	1	1	1	1
Stock-based pay	2	1	1	1	1	2	2
Capital spending	—	0	1	0	0	0	0
Free cash flow	—	−11	−11	−15	−14	−12	−15
Free cash flow after stock pay	—	−12	−13	−17	−16	−14	−17
Shares issued	—	—	—	—	—	—	0

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ARTV vs CLNN ARTV vs CRVO ARTV vs CLDX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Artiva Biotherapeutics, Inc.